Furthermore, a multitarget cross‐activity may be beneficial in cancer patients treated with chemotherapy that develop a distal peripheral neuropathy, where a contribution of TRPM8, TRPV1, and TRPA1 channels has been reported [63]. The gene discussed is TRPM8; the disease is cancer.